Men over 40 who enjoy sex need to worry more about prostate cancer

Jeremy Clarke already had the cancer. But a doctor told his 46-year-old brother he didn't need to be checked. Now they're both fighting for survival.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 2 April 2020Source: Urology Case ReportsAuthor(s): Takashi Ando, Kazuhiro Watanabe, Takaki Mizusawa, Takeshi Sakai, Akiyoshi Katagiri
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: Available online 2 April 2020Source: Urology Case ReportsAuthor(s): Alexandar Blazevski, Amer Amin, Gordon O'Neill
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: Available online 2 April 2020Source: Respiratory Medicine Case ReportsAuthor(s): Caibao Jin, Hui Ren, Yang Hu, Jingyi Wu, Yanping Hu, Zhijun Wang, Youying Wei, Bin Yang, Ling Yang
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Condition:   Metastatic Prostate Cancer Interventions:   Drug: Enzalutamide;   Drug: Talazoparib Sponsors:   MedSIR;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: We report the efficacy and safety of IFX maintained for up to 12 years in psoriasis patients. The long-term use of IFX was associated with a high BMI confirming the critical role of weight-based dosing for this drug. PMID: 32231699 [PubMed]
Source: Dermatology Research and Practice - Category: Dermatology Tags: Dermatol Res Pract Source Type: research
Madam — Docetaxel chemotherapy may be offered to patients with high-risk, hormone-sensitive non-metastatic prostate cancer alongside neoadjuvant androgen deprivation therapy (nADT) prior to treatment with radiotherapy [1]. Prostate-specific antigen (PSA) levels monitor treatment response and fall with n ADT and radiotherapy. Pre-radiotherapy PSA levels measured after nADT have shown some value as a prognostic marker; pre-radiotherapy nadir PSA
Source: Clinical Oncology - Category: Radiology Authors: Tags: Letter Source Type: research
In this study, a unique experimental set-up consisting of a Raman microscope, coupled with a commercial shear-flow microfluidic system is used to monitor fatty acid uptake by prostate cancer (PC-3) cells in real-time at the single cell level. Uptake of deuterated PA, deuterated AA, and the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) were monitored using this new system, while complementary flow cytometry experiments using Nile red staining, were also conducted for the validation of the cellular lipid uptake. Using this novel experimental system, we show that DHA and EPA have inhibitory ef...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
ConclusionsThis study confirms PIRADS has high accuracy, sensitivity and NPV for detecting all CaP and csCaP. A high NPV may obviate need for biopsy in low ‐risk patients.
Source: Journal of Medical Imaging and Radiation Oncology - Category: Radiology Authors: Tags: Medical Imaging —Original Article Source Type: research
In conclusion, the combination of ionizing radiation and oncolytic adenovirus expressing IL24 could achieve synergistic anti-tumor effect on prostate cancer, and is a promising strategy for prostate cancer therapy.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Purpose: Late gastrointestinal (GI) toxicity after radiotherapy for prostate cancer may have significant impact on the cancer survivor's quality of life. To date, little is known about local dose-effects after modern radiotherapy including hypofractionation. In the current study we related the local spatial distribution of radiation dose in the rectum to late patient-reported gastrointestinal (GI) toxicities for conventionally fractionated (CF) and hypofractionated (HF) modern radiotherapy in the randomized HYPRO trial.Material and Methods: Patients treated to 78 Gy in 2 Gy fractions (n = 298) or 64.6 Gy in 3.4 Gy fraction...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Health | Prostate Cancer